Virtus ETF Advisers’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,383
| Closed | -$333K | – | 702 |
|
|
2024
Q4 | $333K | Sell |
7,383
-1,542
| -17% | -$66K | 0.14% | 225 |
|
|
2024
Q3 | $331K | Hold |
8,925
| – | – | 0.15% | 221 |
|
|
2024
Q2 | $273K | Sell |
8,925
-4,880
| -35% | -$158K | 0.13% | 238 |
|
|
2024
Q1 | $402K | Buy |
13,805
+1,986
| +17% | +$55.6K | 0.21% | 194 |
|
|
2023
Q4 | $326K | Buy |
11,819
+4,744
| +67% | +$108K | 0.21% | 211 |
|
|
2023
Q3 | $159K | Sell |
7,075
-914
| -11% | -$34K | 0.1% | 309 |
|
|
2023
Q2 | $325K | Buy |
7,989
+205
| +3% | +$10K | 0.19% | 181 |
|
|
2023
Q1 | $377K | Buy |
7,784
+136
| +2% | +$6.22K | 0.21% | 151 |
|
|
2022
Q4 | $292K | Sell |
7,648
-1,529
| -17% | -$63.6K | 0.15% | 280 |
|
|
2022
Q3 | $461K | Buy |
9,177
+134
| +1% | +$6.57K | 0.18% | 219 |
|
|
2022
Q2 | $362K | Sell |
9,043
-991
| -10% | -$34.7K | 0.13% | 257 |
|
|
2022
Q1 | $374K | Hold |
10,034
| – | – | 0.17% | 156 |
|
|
2021
Q4 | $400K | Sell |
10,034
-382
| -4% | -$14.6K | 0.15% | 150 |
|
|
2021
Q3 | $388K | Sell |
10,416
-952
| -8% | -$39.1K | 0.17% | 179 |
|
|
2021
Q2 | $481K | Buy |
11,368
+1,892
| +20% | +$81.1K | 0.2% | 161 |
|
|
2021
Q1 | $449K | Buy |
9,476
+256
| +3% | +$15.2K | 0.19% | 161 |
|
|
2020
Q4 | $563K | Sell |
9,220
-2,643
| -22% | -$156K | 0.23% | 129 |
|
|
2020
Q3 | $555K | Buy |
11,863
+999
| +9% | +$49.2K | 0.29% | 122 |
|
|
2020
Q2 | $551K | Sell |
10,864
-1,333
| -11% | -$65.5K | 0.26% | 134 |
|
|
2020
Q1 | $544K | Sell |
12,197
-1,029
| -8% | -$51.8K | 0.22% | 167 |
|
|
2019
Q4 | $635K | Buy |
13,226
+6,918
| +110% | +$294K | 0.1% | 174 |
|
|
2019
Q3 | $213K | Sell |
6,308
-352
| -5% | -$15.3K | 0.04% | 235 |
|
|
2019
Q2 | $300K | Sell |
6,660
-1,287
| -16% | -$50.8K | 0.06% | 213 |
|
|
2019
Q1 | $299K | Sell |
7,947
-701
| -8% | -$23.5K | 0.64% | 60 |
|
|
2018
Q4 | $297K | Sell |
8,648
-3,678
| -30% | -$132K | 0.05% | 113 |
|
|
2018
Q3 | $579K | Sell |
12,326
-8,814
| -42% | -$365K | 0.06% | 106 |
|
|
2018
Q2 | $713K | Sell |
21,140
-25,777
| -55% | -$804K | 0.63% | 97 |
|
|
2018
Q1 | $1.27M | Buy |
46,917
+25,165
| +116% | +$638K | 1.1% | 14 |
|
|
2017
Q4 | $363K | Buy |
21,752
+2,140
| +11% | +$36.2K | 0.46% | 74 |
|
|
2017
Q3 | $392K | Buy |
19,612
+1,794
| +10% | +$35.1K | 0.05% | 115 |
|
|
2017
Q2 | $327K | Sell |
17,818
-4,881
| -22% | -$65.8K | 0.05% | 100 |
|
|
2017
Q1 | $223K | Buy |
22,699
+2,176
| +11% | +$26.3K | 0.04% | 161 |
|
|
2016
Q4 | $224K | Sell |
20,523
-14,326
| -41% | -$150K | 0.07% | 166 |
|
|
2016
Q3 | $488K | Hold |
34,849
| – | – | 0.24% | 74 |
|
|
2016
Q2 | $245K | Buy |
34,849
+26,072
| +297% | +$191K | 0.18% | 93 |
|
|
2016
Q1 | $57K | Buy |
+8,777
| New | +$152K | 0.08% | 151 |
|
Other funds holding PTCT
RI
AC
Virtus ETF Advisers's PTCT Position: Q1 2025 in Review
Virtus ETF Advisers sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 7,383 shares — an estimated $333K sold.
Virtus ETF Advisers first reported a position in PTCT in Q1 2016 and held it in 36 quarters. The position peaked at $1.27M in Q1 2018. 260 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.
- Virtus ETF Advisers reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 7,383 PTC Therapeutics shares in Q1 2025, an estimated $333K.
- Virtus ETF Advisers first reported a position in PTC Therapeutics in Q1 2016 and held it in 36 quarters.
- Virtus ETF Advisers's PTC Therapeutics position peaked at $1.27M in Q1 2018.
- 260 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.